Rescue of impaired late-phase long-term depression in a tau transgenic mouse model

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 730-739

  Ahmed, Tariq ^a   Blum, David ^b,c,d   Burnouf, Sylvie ^b,c,e   Demeyer, Dominique ^b,c   Buée Scherrer, Valérie ^b,c,d   D'Hooge, Rudi ^a   Buée, Luc ^b,c,d   Balschun, Detlef ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIV LILLE   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e MAX PLANCK INSTITUTE FOR BIOLOGY OF AGEING   (Germany)

Author keywords

Alzheimer's disease; CA1 region; Glycogen synthase kinase 3; Hippocampus; Long term depression; LTD; Okadaic acid; Protein phosphatase 2A; SB216763; Sodium selenate; Synaptic plasticity; Tauopathy

Indexed keywords

CALCIUM CHANNEL L TYPE; GLYCOGEN SYNTHASE KINASE 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHATASE; SELENATE; SERINE; PHOSPHOPROTEIN PHOSPHATASE 2; TAU PROTEIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HIPPOCAMPUS; LEARNING; LONG TERM DEPRESSION; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PROTEIN DEPHOSPHORYLATION; TAUOPATHY; TRANSGENIC MOUSE; ALZHEIMER DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSION; DISEASE MODEL; GENETICS; LONG TERM POTENTIATION; MEMORY; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION; PHYSIOLOGY; PSYCHOLOGY;

ALZHEIMER DISEASE; ANIMALS; DEPRESSION; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; LEARNING; LONG-TERM POTENTIATION; MALE; MEMORY; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; TAU PROTEINS;

EID: 84922802062     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.09.015     Document Type: Article

References (96)

1. Agarwal-Mawal A., Qureshi H.Y., Cafferty P.W., Yuan Z., Han D., Lin R., Paudel H.K. 14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex. J.Biol. Chem. 2003, 278:12722-12728.
2. Ahmed T., Sabanov V., D'Hooge R., Balschun D. An N-methyl-D-aspartate-receptor dependent, late-phase long-term depression in middle-aged mice identifies no GluN2-subunit bias. Neuroscience 2011, 185:27-38.
3. Alexander G., Hanna A., Serna V., Younkin L., Younkin S., Janus C. Increased aggression in males in transgenic Tg2576 mouse model of Alzheimer's disease. Behav. Brain Res. 2011, 216:77-83.
4. Alonso A.D., Zaidi T., Novak M., Barra H.S., Grundke-Iqbal I., Iqbal K. Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and invitro phosphorylation into the disease-like protein. J.Biol. Chem. 2001, 276:37967-37973.
5. Belarbi K., Burnouf S., Fernandez-Gomez F.J., Desmercieres J., Troquier L., Brouillette J., Tsambou L., Grosjean M.E., Caillierez R., Demeyer D., Hamdane M., Schindowski K., Blum D., Buee L. Loss of medial septum cholinergic neurons in THY-Tau22 mouse model: what links with tau pathology?. Curr. Alzheimer Res. 2011, 8:633-638.
6. Belarbi K., Schindowski K., Burnouf S., Caillierez R., Grosjean M.E., Demeyer D., Hamdane M., Sergeant N., Blum D., Buee L. Early tau pathology involving the septo-hippocampal pathway in a tau transgenic model: relevance to Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:152-157.
7. Benilova I., Karran E., De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 2012, 15:349-357.
8. Bhat R.V., Budd Haeberlein S.L., Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J.Neurochem. 2004, 89:1313-1317.
9. Bliss T.V., Collingridge G.L. Asynaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
10. Braak H., de Vos R.A., Jansen E.N., Bratzke H., Braak E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog. Brain Res. 1998, 117:267-285. 267-285.
11. Braak H., Del T.K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011, 121:171-181.
12. Brigman J.L., Wright T., Talani G., Prasad-Mulcare S., Jinde S., Seabold G.K., Mathur P., Davis M.I., Bock R., Gustin R.M., Colbran R.J., Alvarez V.A., Nakazawa K., Delpire E., Lovinger D.M., Holmes A. Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning. J.Neurosci. 2010, 30:4590-4600.
13. Brion J.P., Couck A.M., Passareiro E., Flament-Durand J. Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study. J.Submicrosc Cytol. 1985, 17:89-96.
14. Brouillette J., Caillierez R., Zommer N., Alves-Pires C., Benilova I., Blum D., De S.B., Buee L. Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-beta1-42 oligomers are revealed invivo by using a novel animal model. J.Neurosci. 2012, 32:7852-7861.
15. Brozmanova J., Manikova D., Vlckova V., Chovanec M. Selenium: a double-edged sword for defense and offence in cancer. Arch. Toxicol. 2010, 84:919-938.
16. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000, 33:95-130.
17. Burnouf S., Martire A., Derisbourg M., Laurent C., Belarbi K., Leboucher A., Fernandez-Gomez F.J., Troquier L., Eddarkaoui S., Grosjean M.E., Demeyer D., Muhr-Tailleux A., Buisson A., Sergeant N., Hamdane M., Humez S., Popoli P., Buee L., Blum D. NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a tau transgenic model. Aging Cell 2012, 12:11-23.
18. Chakroborty S., Kim J., Schneider C., Jacobson C., Molgo J., Stutzmann G.E. Early presynaptic and postsynaptic calcium signaling abnormalities mask underlying synaptic depression in presymptomatic Alzheimer's disease mice. J.Neurosci. 2012, 32:8341-8353.
19. Chang E.H., Savage M.J., Flood D.G., Thomas J.M., Levy R.B., Mahadomrongkul V., Shirao T., Aoki C., Huerta P.T. AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:3410-3415.
20. Chen P., Gu Z., Liu W., Yan Z. Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons. Mol. Pharmacol. 2007, 72:40-51.
21. Chen Q.S., Kagan B.L., Hirakura Y., Xie C.W. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J.Neurosci. Res. 2000, 60:65-72.
22. Cheng L., Yin W.J., Zhang J.F., Qi J.S. Amyloid beta-protein fragments 25-35 and 31-35 potentiate long-term depression in hippocampal CA1 region of rats invivo. Synapse 2009, 63:206-214.
23. Cheung Z.H., Ip N.Y. Cdk5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol. 2012, 22:169-175.
24. Citri A., Malenka R.C. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 2008, 33:18-41.
25. Collingridge G.L., Peineau S., Howland J.G., Wang Y.T. Long-term depression in the CNS. Nat. Rev. Neurosci. 2010, 11:459-473.
26. Corcoran N.M., Martin D., Hutter-Paier B., Windisch M., Nguyen T., Nheu L., Sundstrom L.E., Costello A.J., Hovens C.M. Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J.Clin. Neurosci. 2010, 17:1025-1033.
27. Crespo-Biel N., Theunis C., Borghgraef P., Lechat B., Devijver H., Maurin H., Van L.F. Phosphorylation of protein tau by GSK3beta prolongs survival of bigenic tau.P301LxGSK3beta mice by delaying brainstem tauopathy. Neurobiol. Dis. 2014, 67:119-132.
28. Cullen W.K., Suh Y.H., Anwyl R., Rowan M.J. Block of LTP in rat hippocampus invivo by beta-amyloid precursor protein fragments. Neuroreport 1997, 8:3213-3217.
29. Deshpande A., Kawai H., Metherate R., Glabe C.G., Busciglio J. Arole for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J.Neurosci. 2009, 29:4004-4015.
30. Deshpande A., Mina E., Glabe C., Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J.Neurosci. 2006, 26:6011-6018.
31. Di P.M., Macaluso E., Carlesimo G.A., Tomaiuolo F., Worsley K.J., Fadda L., Caltagirone C. Episodic memory impairment in patients with Alzheimer's disease is correlated with entorhinal cortex atrophy. A voxel-based morphometry study. J.Neurol. 2007, 254:774-781.
32. Engel T., Hernandez F., Avila J., Lucas J.J. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J.Neurosci. 2006, 26:5083-5090.
33. Engmann O., Giese K.P. Crosstalk between Cdk5 and GSK3beta: implications for Alzheimer's disease. Front. Mol. Neurosci. 2009, 2:2.
34. Foster T.C. Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell 2007, 6:319-325.
35. Glodzik L., de S.S., Tsui W.H., Mosconi L., Zinkowski R., Pirraglia E., Wang H.Y., Li Y., Rich K.E., Zetterberg H., Blennow K., Mehta P., de Leon M.J. Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol. Aging 2011, 32:2131-2141.
36. Goh J.J., Manahan-Vaughan D. Spatial object recognition enables endogenous LTD that curtails LTP in the mouse hippocampus. Cereb. Cortex 2012, 23:1118-1125.
37. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
38. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
39. Hashiguchi M., Hashiguchi T. Kinase-kinase interaction and modulation of tau phosphorylation. Int. Rev. Cell Mol. Biol. 2013, 300:121-160.
40. Hong M., Chen D.C., Klein P.S., Lee V.M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J.Biol. Chem. 1997, 272:25326-25332.
41. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J.Neurochem. 2008, 104:1433-1439.
42. Hoover B.R., Reed M.N., Su J., Penrod R.D., Kotilinek L.A., Grant M.K., Pitstick R., Carlson G.A., Lanier L.M., Yuan L.L., Ashe K.H., Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68:1067-1081.
43. Hornberger M., Piguet O. Episodic memory in frontotemporal dementia: a critical review. Brain 2012, 135:678-692.
44. Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006, 52:831-843.
45. Jones N.C., Nguyen T., Corcoran N.M., Velakoulis D., Chen T., Grundy R., O'Brien T.J., Hovens C.M. Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. Neurobiol. Dis. 2012, 45:897-901.
46. Kemp A., Manahan-Vaughan D. Hippocampal long-term depression: master or minion in declarative memory processes?. Trends Neurosci. 2007, 30:111-118.
47. Kim J.H., Anwyl R., Suh Y.H., Djamgoz M.B., Rowan M.J. Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus invivo. J.Neurosci. 2001, 21:1327-1333.
48. Kins S., Crameri A., Evans D.R., Hemmings B.A., Nitsch R.M., Gotz J. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J.Biol. Chem. 2001, 276:38193-38200.
49. Koh S.H., Noh M.Y., Kim S.H. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res. 2008, 1188:254-262.
50. Kremer A., Louis J.V., Jaworski T., Van L.F. GSK3 and Alzheimer's disease: facts and fiction. Front. Mol. Neurosci. 2011, 4:17.
51. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., Klein W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J.Neurosci. 2007, 27:796-807.
52. Lasagna-Reeves C.A., Castillo-Carranza D.L., Sengupta U., Guerrero-Munoz M.J., Kiritoshi T., Neugebauer V., Jackson G.R., Kayed R. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2012, 2:700.
53. Lee S., Hall G.F., Shea T.B. Potentiation of tau aggregation by cdk5 and GSK3beta. J.Alzheimers Dis. 2011, 26:355-364.
54. Lee V.M., Brunden K.R., Hutton M., Trojanowski J.Q. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb. Perspect. Med. 2011, 1:a006437.
55. Leroy K., Yilmaz Z., Brion J.P. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol. Appl. Neurobiol. 2007, 33:43-55.
56. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
57. Liu C., Gotz J. How it all started: tau and protein phosphatase 2A. J.Alzheimers Dis. 2013, 37:483-494.
58. Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 2005, 22:1942-1950.
59. Louis J.V., Martens E., Borghgraef P., Lambrecht C., Sents W., Longin S., Zwaenepoel K., Pijnenborg R., Landrieu I., Lippens G., Ledermann B., Gotz J., Van L.F., Goris J., Janssens V. Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:6957-6962.
60. Lyketsos C.G., Carrillo M.C., Ryan J.M., Khachaturian A.S., Trzepacz P., Amatniek J., Cedarbaum J., Brashear R., Miller D.S. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 2011, 7:532-539.
61. Mandelkow E.M., Biernat J., Drewes G., Gustke N., Trinczek B., Mandelkow E. Tau domains, phosphorylation, and interactions with microtubules. Neurobiol. Aging 1995, 16:355-362.
62. Martin L., Page G., Terro F. Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3beta. Neurochem. Int. 2011, 59:235-250.
63. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
64. Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Haute C.V., Checler F., Godaux E., Cordell B., Van Leuven F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J.Biol. Chem. 1999, 274:6483-6492.
65. Morice E., Billard J.M., Denis C., Mathieu F., Betancur C., Epelbaum J., Giros B., Nosten-Bertrand M. Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology 2007, 32:2108-2116.
66. Nelson P.T, Alafuzoff I., Bigio E.H., Bouras C., Braak H., Cairns N.J., Castellani R.J., Crain B.J., Davies P., Del T.K., Duyckaerts C., Frosch M.P., Haroutunian V., Hof P.R., Hulette C.M., Hyman B.T., Iwatsubo T., Jellinger K.A., Jicha G.A., Kovari E., Kukull W.A., Leverenz J.B., Love S., Mackenzie I.R., Mann D.M., Masliah E., McKee A.C., Montine T.J., Morris J.C., Schneider J.A., Sonnen J.A., Thal D.R., Trojanowski J.Q., Troncoso J.C., Wisniewski T., Woltjer R.L., Beach T.G. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J.Neuropathol. Exp. Neurol. 2012, 71:362-381.
67. Nestor P.J., Fryer T.D., Hodges J.R. Declarative memory impairments in Alzheimer's disease and semantic dementia. Neuroimage 2006, 30:1010-1020.
68. Nicholls R.E., Alarcon J.M., Malleret G., Carroll R.C., Grody M., Vronskaya S., Kandel E.R. Transgenic mice lacking NMDAR-dependent LTD exhibit deficits in behavioral flexibility. Neuron 2008, 58:104-117.
69. Peineau S., Nicolas C.S., Bortolotto Z.A., Bhat R.V., Ryves W.J., Harwood A.J., Dournaud P., Fitzjohn S.M., Collingridge G.L. Asystematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases. Mol. Brain 2009, 2:22.
70. Peineau S., Taghibiglou C., Bradley C., Wong T.P., Liu L., Lu J., Lo E., Wu D., Saule E., Bouschet T., Matthews P., Isaac J.T., Bortolotto Z.A., Wang Y.T., Collingridge G.L. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 2007, 53:703-717.
71. Plattner F., Angelo M., Giese K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J.Biol. Chem. 2006, 281:25457-25465.
72. Price D.L., Bonhaus D.W., McFarland K. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. Behav. Pharmacol. 2012, 23:426-433.
73. Qian W., Shi J., Yin X., Iqbal K., Grundke-Iqbal I., Gong C.X., Liu F. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J.Alzheimers Dis. 2010, 19:1221-1229.
74. Rowan M.J., Klyubin I., Cullen W.K., Anwyl R. Synaptic plasticity in animal models of early Alzheimer's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2003, 358:821-828.
75. SantaCruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
76. Schindowski K., Bretteville A., Leroy K., Begard S., Brion J.P., Hamdane M., Buee L. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 2006, 169:599-616.
77. Seabrook G.R., Rosahl T.W. Transgenic animals relevant to Alzheimer's disease. Neuropharmacology 1999, 38:1-17.
78. Sergeant N., Bretteville A., Hamdane M., Caillet-Boudin M.L., Grognet P., Bombois S., Blum D., Delacourte A., Pasquier F., Vanmechelen E., Schraen-Maschke S., Buee L. Biochemistry of tau in Alzheimer's disease and related neurological disorders. Expert Rev. Proteomics 2008, 5:207-224.
79. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
80. Shukla V., Skuntz S., Pant H.C. Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch. Med. Res. 2012, 43:655-662.
81. Song G., Zhang Z., Wen L., Chen C., Shi Q., Zhang Y., Ni J., Liu Q. Selenomethionine ameliorates cognitive decline, reduces tau hyperphosphorylation, and reverses synaptic deficit in the triple transgenic mouse model of Alzheimer's disease. J.Alzheimers Dis. 2014, 41:85-99.
82. Sontag E., Luangpirom A., Hladik C., Mudrak I., Ogris E., Speciale S., White C.L. Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J.Neuropathol. Exp. Neurol. 2004, 63:287-301.
83. Sontag J.M., Nunbhakdi-Craig V., White C.L., Halpain S., Sontag E. The protein phosphatase PP2A/Balpha binds to the microtubule-associated proteins tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies. J.Biol. Chem. 2012, 287:14984-14993.
84. Sontag J.M., Sontag E. Protein phosphatase 2A dysfunction in Alzheimer's disease. Front. Mol. Neurosci. 2014, 7:16.
85. Sydow A., Van Der Jeugd A., Zheng F., Ahmed T., Balschun D., Petrova O., Drexler D., Zhou L., Rune G., Mandelkow E., D'Hooge R., Alzheimer C., Mandelkow E.M. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic tau mutant. J.Neurosci. 2011, 31:2511-2525.
86. Takashima A. GSK-3beta and memory formation. Front. Mol. Neurosci. 2012, 5:47.
87. Ting J.T., Kelley B.G., Lambert T.J., Cook D.G., Sullivan J.M. Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:353-358.
88. Townsend M., Shankar G.M., Mehta T., Walsh D.M., Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J.Physiol. 2006, 572:477-492.
89. Van der Jeugd A., Ahmed T., Burnouf S., Belarbi K., Hamdame M., Grosjean M.E., Humez S., Balschun D., Blum D., Buee L., D'Hooge R. Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol. Learn Mem. 2011, 95:296-304.
90. Van Der Jeugd A., Blum D., Raison S., Eddarkaoui S., Buee L., D'Hooge R. Observations in THY-Tau22 mice that resemble behavioral and psychological signs and symptoms of dementia. Behav. Brain Res. 2013, 242:34-39.
91. Van der Jeugd A., Hochgrafe K., Ahmed T., Decker J.M., Sydow A., Hofmann A., Wu D., Messing L., Balschun D., D'Hooge R., Mandelkow E.M. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol. 2012, 123:787-805.
92. van Eersel J., Ke Y.D., Liu X., Delerue F., Kril J.J., Gotz J., Ittner L.M. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13888-13893.
93. Van Spronsen M., Hoogenraad C.C. Synapse pathology in psychiatric and neurologic disease. Curr. Neurol. Neurosci. Rep. 2010, 10:207-214.
94. Winder D.G., Sweatt J.D. Roles of serine/threonine phosphatases in hippocampal synaptic plasticity. Nat. Rev. Neurosci. 2001, 2:461-474.
95. Yuan Z., Agarwal-Mawal A., Paudel H.K. 14-3-3 binds to and mediates phosphorylation of microtubule-associated tau protein by Ser9-phosphorylated glycogen synthase kinase 3beta in the brain. J.Biol. Chem. 2004, 279:26105-26114.
96. Zeng H., Chattarji S., Barbarosie M., Rondi-Reig L., Philpot B.D., Miyakawa T., Bear M.F., Tonegawa S. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 2001, 107:617-629.